• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

ARQL:US

1.4300 USD 0.0200 1.42%

As of 20:10:00 ET on 07/10/2014.

Snapshot for ArQule Inc (ARQL)

Open: 1.3900 Day's Range: 1.3500 - 1.4300 Volume: 462,569
Previous Close: 1.4100 52wk Range: 1.2900 - 2.9400 1-Yr Rtn: -47.43%

Stock Chart for ARQL

No chart data available.
  • ARQL:US 1.4200
  • 1D
  • 1M
  • 1Y
1.4100
Interactive ARQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ARQL

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.4196
Est. EPS (USD) (12/2014) -0.5060
Est. PEG Ratio -
Market Cap (M USD) 89.69
Shares Outstanding (M) 62.72
30 Day Average Volume 1,139,293
Price/Book (mrq) 1.6441
Price/Sale (ttm) 6.9150
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/30/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ARQL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ARQL

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrWilliam B BoniVP:Investor Relations
More Company Profile & Key Executives for ARQL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil